The increased necessity of chemical characterization in biocompatibility assessment and particularly its significance creates an interesting and necessary clarification of the "how" of the biocompatibility assessment for all involved. In this context, the FDA aims to achieve consistency and reliability for more efficient assessment by specifying methodologies.